Chargement des cours...
Prévisions
| Acheter |
1 |
| Conserver |
1 |
| Vendre |
0 |
Actualités Accéder au fil d'actualités
Aclarion: scan volume H1 2026 up 141%
Aclarion reports scan‑volume growth of 141% year‑on‑year and 71% sequentially for the first half of 2026, driven by rising adoption of the Nociscan platform. As of 30 June the company had USD 16.3 million in cash and was debt‑free; management says funds will last into H2 2027. Aclarion secured reimbursement from three major UK private insurers (Vitality, Axa, Aviva) and has launched a US market‑access program with PRIA Healthcare. The CLARITY study was expanded and a first interim readout is expected in 2026; the patent portfolio now comprises 65 granted and pending patents worldwide. » Plus sur de.investing.com
Données financières de l'entreprise
| (EUR) | juin 2026 | YoY |
|---|---|---|
| Chiffre d'affaires | 22,09 k | 34,76 % |
| Bénéfice brut | 7,27 k | 66,71 % |
| Bénéfice net | -2,41 M | 77,26 % |
| EBITDA | -2,35 M | 79,15 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 4,97 M € |
Nombre d'actions | 2,88 M |
Plus haut/bas sur 52 semaines | 8,36 € - 1,65 € |
| Dividendes | Non |
Bêta | 1,21 |
Ratio P/E | -0,25 |
Ratio PEG | 0,00 |
Ratio P/B | 0,28 |
Ratio P/S | 66,41 |
Profil de l'entreprise
| Nom | ACLARION NEW DL-,00001 |
| PDG | Brent Ness |
| Employés | 11 |
